ABBV vs. LLY: AbbVie vs. Eli Lilly Stock Comparison
How do AbbVie (ABBV) and Eli Lilly (LLY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
AbbVie (ABBV) and Eli Lilly (LLY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ABBV is classified in Biotechnology while LLY is classified in Pharmaceuticals.
| Profile Item | ABBV | LLY |
|---|---|---|
| Name | AbbVie Inc. | Eli Lilly and Company |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Pharmaceuticals |
| GICS Sub-Industry | Biotechnology | Pharmaceuticals |
| Market Capitalization | 521.50 billion USD | 1,285.79 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | NYSE |
| Listing Date | January 2, 2013 | June 1, 1972 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ABBV | LLY |
|---|---|---|
| Total Return (1Y) | 30.81% | 42.18% |
| Total Return (3Y, Annualized) | 32.97% | 34.03% |
| Total Return (5Y, Annualized) | 24.68% | 42.16% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ABBV | LLY |
|---|---|---|
| Volatility (1Y, Annualized) | 25.21% | 35.25% |
| Beta (5Y) | 0.20 | 0.39 |
| Max Drawdown (5Y) | -21.92% | -34.48% |
| Avg. Volume (3M) | 4.78M | 2.56M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ABBV | LLY |
|---|---|---|
| Sharpe Ratio (1Y) | 1.04 | 1.06 |
| Sortino Ratio (1Y) | 1.61 | 1.79 |
Profitability
ROE (TTM)
Capital efficiency shows on one side only: Eli Lilly (LLY) earns 86.02% on shareholders’ equity, ranked against its industry; AbbVie (ABBV) has no ROE this period.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.99%
- Median
- -27.11%
- Q1
- -63.32%
- Min
- -153.84%
- ABBV
- --
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
86.02%
- Max
- 109.18%
- LLY
- 86.02%
- Q3
- 6.99%
- Median
- -27.11%
- Q1
- -63.32%
- Min
- -153.84%
Net Margin (TTM)
Eli Lilly (LLY) at 31.90% keeps the most of each sales dollar — above its industry’s net margin range — and AbbVie (ABBV) at 15.67% also retains a top-quartile share.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
15.67%
- Max
- 20.27%
- ABBV
- 15.67%
- Q3
- 4.98%
- Median
- 0.00%
- Q1
- -5.28%
- Min
- -18.66%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.90%
- LLY
- 31.90%
- Max
- 20.27%
- Q3
- 4.98%
- Median
- 0.00%
- Q1
- -5.28%
- Min
- -18.66%
Operating Margin (TTM)
Both AbbVie (ABBV) at 36.64% and Eli Lilly (LLY) at 51.25% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
36.64%
- Max
- 80.14%
- ABBV
- 36.64%
- Q3
- 12.89%
- Median
- 0.00%
- Q1
- -69.33%
- Min
- -189.53%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
51.25%
- Max
- 80.14%
- LLY
- 51.25%
- Q3
- 12.89%
- Median
- 0.00%
- Q1
- -69.33%
- Min
- -189.53%
Profitability Metrics
| Metric | ABBV | LLY |
|---|---|---|
| ROE (TTM) | -- | 86.02% |
| ROA (TTM) | 10.74% | 21.06% |
| Net Margin (TTM) | 15.67% | 31.90% |
| Operating Margin (TTM) | 36.64% | 51.25% |
| Gross Margin (TTM) | 73.72% | 83.63% |
Growth
Revenue Growth
Both AbbVie (ABBV) at 8.57% and Eli Lilly (LLY) at 44.70% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Eli Lilly (LLY) at 95.99% sits in the top EPS growth quartile, while AbbVie (ABBV) at -0.84% is closer to the peer norm — faster per-share earnings growth for LLY.
Growth Metrics
| Metric | ABBV | LLY |
|---|---|---|
| Revenue Growth (YoY) | 8.57% | 44.70% |
| Revenue Growth (3Y CAGR) | 1.75% | 31.69% |
| EPS Growth (YoY) | -0.84% | 95.99% |
| EPS Growth (3Y CAGR) | -29.03% | 51.71% |
Financial Strength
Current Ratio (MRQ)
Both AbbVie (ABBV) at 0.87 and Eli Lilly (LLY) at 1.39 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.87
- Max
- 23.95
- Q3
- 11.76
- Median
- 5.04
- Q1
- 2.44
- ABBV
- 0.87
- Min
- 0.10
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.39
- Max
- 23.95
- Q3
- 11.76
- Median
- 5.04
- Q1
- 2.44
- LLY
- 1.39
- Min
- 0.10
Debt / Equity (MRQ)
Only one side’s leverage can be read here: Eli Lilly (LLY) carries debt-to-equity ratio of 1.23 against its industry range, while AbbVie (ABBV) reports no figure this period.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.44
- Q3
- 0.66
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- ABBV
- --
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.23
- Max
- 1.44
- LLY
- 1.23
- Q3
- 0.66
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ABBV | LLY |
|---|---|---|
| Current Ratio (MRQ) | 0.87 | 1.39 |
| Debt / Equity (MRQ) | -- | 1.23 |
| Net Debt / EBITDA | 2.21 | 0.96 |
Dividends
Dividend Yield (TTM)
Both AbbVie (ABBV) at 2.35% and Eli Lilly (LLY) at 0.47% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.35%
- ABBV
- 2.35%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.47%
- LLY
- 0.47%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
AbbVie (ABBV) reports payout ratio above 100% at 117.35%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Eli Lilly (LLY) reports 21.71%, ranking against industry peers normally.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
117.35%
- ABBV
- 117.35%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.71%
- LLY
- 21.71%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ABBV | LLY |
|---|---|---|
| Dividend Yield (TTM) | 2.35% | 0.47% |
| Dividend Payout Ratio (TTM) | 117.35% | 21.71% |
Valuation
P/E Ratio (TTM)
Both AbbVie (ABBV) at 50.69 and Eli Lilly (LLY) at 46.85 sit in the richer earnings-multiple quartile for P/E ratio, so investors are paying more for TTM earnings than they pay for typical peers.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
50.69
- Max
- 89.00
- ABBV
- 50.69
- Q3
- 46.79
- Median
- 27.68
- Q1
- 14.13
- Min
- 0.06
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
46.85
- Max
- 89.00
- LLY
- 46.85
- Q3
- 46.79
- Median
- 27.68
- Q1
- 14.13
- Min
- 0.06
P/S Ratio (TTM)
On P/S ratio, both AbbVie (ABBV) at 7.90 and Eli Lilly (LLY) at 14.87 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.90
- Max
- 48.61
- Q3
- 22.40
- ABBV
- 7.90
- Median
- 6.95
- Q1
- 3.09
- Min
- 0.01
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.87
- Max
- 48.61
- Q3
- 22.40
- LLY
- 14.87
- Median
- 6.95
- Q1
- 3.09
- Min
- 0.01
P/B Ratio (MRQ)
AbbVie (ABBV) reports a negative P/B ratio of -113.78, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Eli Lilly (LLY) reports 31.95, ranking against industry peers normally.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
-113.78
- Max
- 13.20
- Q3
- 6.63
- Median
- 3.27
- Q1
- 1.80
- Min
- -5.40
- ABBV
- -113.78
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.95
- LLY
- 31.95
- Max
- 13.20
- Q3
- 6.63
- Median
- 3.27
- Q1
- 1.80
- Min
- -5.40
Valuation Metrics
| Metric | ABBV | LLY |
|---|---|---|
| P/E Ratio (TTM) | 50.69 | 46.85 |
| P/S Ratio (TTM) | 7.90 | 14.87 |
| P/B Ratio (MRQ) | -113.78 | 31.95 |
| Free Cash Flow Yield (TTM) | 3.39% | 0.73% |